 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF said it has obtained positive results from a preclinical neural plasticity study of BETR-001 in cortical rat neurons, as part of its collaboration with the laboratory of Dr Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. BETR-001 2-bromo-LSD, formerly TD-0148A is a non-hallucinogenic derivative of lysergic acid diethylamide LSD. 